Cardiovascular risk of SCORE compared to Framingham. Consequences of the change proposed by the European Societies;Riesgo cardiovascular del SCORE comparado con el de Framingham. Consecuencias del cambio propuesto por las Sociedades Europeas

Medicina Clinica

Volumn 123, Issue 18, 2004, Pages 681-685

  Maiques Galán, Antonio ^a   García, Francisco Antón ^b   Taix, María Franch ^a   Ros, Xavier Albert ^a   Aleixandre Martí, Eugenia ^a   Collado Gil, Angel ^c  

^a Centro de Salud Nazaret   (Spain)

^b Ctro Sanitario Virgen de Fuensanta   (Spain)

^c Centro de Salud Fuente de San Luis   (Spain)

Author keywords

Cardiovascular disease; Cardiovascular risk; Cardiovascular risk ecuations

Indexed keywords

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; EUROPE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT CODING; PRIMARY MEDICAL CARE; SCORING SYSTEM;

EID: 11244270567     PISSN: 00257753     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0025-7753(04)75330-0     Document Type: Article

References (20)

1. De Backer G, Ambrosioni E, Borch-Johnsen K, Brotons C, Cifkova R, Dallongeville J, et al. Executive summary. European guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J 2003;24:1601-10.
2. Conroy RM, Pyörälä K, Fitzgerald AP, Sans S, Menotti A, De Backer G, et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 2003;24: 987-1003.
3. Pyörälä K, De Backer G, Graham I, Poole-Wilson P, Wood D. Prevention of coronary heart disease in clinical practice. Recomendations of the Task Force of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension. Eur Heart J 1994;15: 1300-31.
4. Wood D, De Backe G, Faegerman O, Graham I, Mancia G, Pyörala K. Prevention of coronary heart disease in clinical practice. Recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention. Eur Heart J 1998;19:1434-503.
5. Menotti A, Lanti M, Puddu E, Kromhout D. Coronary heart disease incidence in northern and southern European population: a reanalysis of the seven countries study for a European coronary risk chart. Heart 2000;84:238-44.
6. Ministerio de Sanidad y Consumo. Control de la hipercolesterolemia en España, 2000. Un instrumento para la prevención cardiovascular. 2000. Madrid, Secretaría General Técnica del Ministerio de Sanidad y Consumo.
7. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of TheThird Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III, or ATP III). JAMA 2001;285: 2486-97.
8. Villar Álvarez F, Maiques Galán A, Brotons Cuixart C, Torcal Laguna J, Ortega Sánchez-Pinilla R, Vilaseca Canals J, et al. Actividades preventivas cardiovasculares en atención primaria. Aten Primaria 2003;32(Supl 2):27-41.
9. Antón F, Maiques A, Franch M, Aleixandre E, Gómez AB, Sotoca R. Efectividad de la prevención cardiovascular en atención primaria. Aten Primaria 2002;28:642-8.
10. Anderson KM, Wilson PWF, Odell PM, Kannel WB. Un update coronary risk profile. A statement for health professionals. Circulation 1991; 83:356-62.
11. Shepherd J, Cobbe S, Ford I, Isles C, Ross A, Macfarlane P. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995;333:1301-7.
12. Frick MH, Elo O, Haapa K. Helsinki Heart Study: primary prevention trial with gemfibrozil in middle-aged men with dyslipidaemia. N Engl J Med 1987;317:1237-45.
13. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA. Primary Prevention of Acute Coronary Events With Lovastatin in Men and Women With Average Cholesterol Levels. Results of AFCAPS/TexCAPS. JAMA 1998;279:1615-22.
14. Pignone M, Phillips C, Mulrow C. Use of lipid lowering drugs for primary prevention for coronary heart disease: meta-analysis of randomised trials. BMJ 2000;321:1-5.
15. Walsh J, Pignone M. Drug treatment of hyperlipidemia in women. JAMA 2004;291:2243-52.
16. The Stroke Council. Statins after ischemic stroke and transient ischemic attack. Stroke 2004;35: 1023.
17. Banegas JR, Villar F, Pérez C, Jiménez R, Gil E, Muñiz J, et al. Estudio epidemiológico de los factores de riesgo cardiovascular en la población española de 35 a 64 años. Rev San Hig Púb 1993; 67:419-45.
18. Gutiérrez Fuentes JA, Gómez Gerique J, Gómez de la Cámara A, Rubio MA, Garcia Hernández A, Aristegui I. Dieta y riesgo cardiovascular en España (DRECE II). Descripción de la evolución del perfil cardiovascular. Med Clin (Barc) 2000;115:726-9.
19. Marrugat J, Solanas P, D'Agostino R, Sullivan L, Ordovas J, Cordón F, et al. Estimación del riesgo coronario en España mediante la ecuación de Framingham calibrada. Rev Esp Cardiol 2003; 56:253-61.
20. Ramos R, Solanas P, Cordón F, Rolfs I, Elosua R, Sala J, et al. Comparación de la función de Framingham original y la calibrada del REGICOR en la predicción del riesgo coronario poblacional. Med Clin (Barc) 2003;121:521-6.